Journey Medical (DERM) Short term Debt (2021 - 2026)

Journey Medical has reported Short term Debt for 5 years, with the latest figure at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt rose 33.33% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (up 33.33% YoY), and the FY2022 full-year result was $2.9 million, up 263.05% from the prior year.
• Short term Debt for Q1 2026 stood at $2.5 million, down from $5.6 million in the prior quarter.
• The five-year high for Short term Debt was $9.9 million in Q2 2023, with the low at $1.9 million in Q1 2025.
• Historically, Short term Debt has averaged $5.2 million across 4 years, with a median of $3.8 million in 2025.
• Annual changes were most pronounced in 2022 — Short term Debt soared 263.05% — and 2026, when it jumped 33.33%.
• Journey Medical's Short term Debt stood at $2.9 million in 2022, then jumped by 237.25% to $9.9 million in 2023, then slumped by 43.42% to $5.6 million in 2025, then slumped by 55.56% to $2.5 million in 2026.
• The last three Short term Debt figures came in at $2.5 million (Q1 2026), $5.6 million (Q3 2025), and $3.8 million (Q2 2025), per Business Quant data.